Cited by 978Pharmaceutical Economics and PolicyBiosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Biopharmaceutical benchmarks 2018

Walsh, Gary·2018·Nature Biotechnology

DOI 10.1038/nbt.4305

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1038/nbt.4305

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76

Show all 3 references

Research works printed but not linked: 11

Walsh, G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32, 992–1000 (2014). · DOI · Paper page
Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010). · DOI
Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24, 769–776 (2006). · DOI
Bertolini, L.R. et al. The transgenic animal platform for biopharmaceutical production. Transgenic Res. 25, 329–343 (2016). · DOI
Park, T.S. et al. Deposition of bioactive human epidermal growth factor in the egg white of transgenic hens using an oviduct-specific minisynthetic promoter. FASEB J. 29, 2386–2396 (2015). · DOI
Miliotou, A.N. & Papadopoulou, L.C. CAR T-cell therapy: a new era in cancer immunotherapy. Curr. Pharm. Biotechnol. 19, 5–18 (2018). · DOI
Kaplon, H. & Reichert, J.M. Antibodies to watch in 2018. MAbs 10, 183–203 (2018). · DOI
Zheng, P.P., Kros, J.M. & Li, J. Approved CAR-T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today 23 1175–1182 (2018). · DOI
Labanieh, L., Majzner, R.G. & Mackall, C.L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377–391 (2018). · DOI
Köhl, U., Arsenieva, S., Holzinger, A. & Abken, H. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum. Gene Ther. 29, 559–568 (2018). · DOI
Klinger, M., Benjamin, J., Kischel, R., Stienen, S. & Zugmaier, G. Harnessing T cells to fight cancer with BiTE® antibody constructs—past developments and future directions. Immunol. Rev. 270, 193–208 (2016). · DOI

Sorted by citations

Items 401–500 of 849

Template-Assisted Crystallization Behavior in Stirred Solutions of the Monoclonal Antibody Anti-CD20: Probability Distributions of Induction Times
Gerard, C. J. J., Briuglia, M. L., Rajoub, N., Mastropietro, T. F., Chen, W., Heng, J. Y. Y., Profio, G. D., & ter Horst, J. H. (2022) · Crystal Growth & Design · doi:10.1021/acs.cgd.1c01324 · Cited by 15
Achieving charge variant profile of innovator molecule during development of monoclonal antibody based biosimilars – use of media components
Gangwar, N., Priyanka, P., & Rathore, A. (2022) · Biochemical engineering journal · doi:10.1016/j.bej.2022.108438 · Cited by 11
Population balance modelling captures host cell protein dynamics in CHO cell cultures
Alhuthali, S., & Kontoravdi, C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265886 · Cited by 13
“Chinese hamster ovary (CHO) cells are the most commonly used host for industrial mAb production, accounting for 84% of currently approved products [2].”
Background
Dual-recognition membrane Adsorbers combining hydrophobic charge-induction chromatography with surface imprinting via multicomponent reaction.
Guo, M., Ye, J.-L., Zheng, C.-Y., & Meng, J. (2022) · Journal of Chromatography A · doi:10.1016/j.chroma.2022.462918 · Cited by 11
Small molecule epigenetic modulators for enhancing recombinant antibody production in CHO cell cultures
Kim, D., Yoon, C., & Lee, G. M. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.28013 · Cited by 11
“For decades, Chinese hamster ovary (CHO) cells have routinely been used for the production of therapeutic proteins (Walsh, 2018; Wurm, 2004).”
Background
Rational design and construction of multi-copy biomanufacturing islands in mammalian cells
Altamura, R., Doshi, J., & Benenson, Y. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1214 · Cited by 10
“Mammalian expression systems are the platform of choice for the production of many high-value biologics, such as recombinant monoclonal antibodies and other recombinant therapeutic proteins, due to their inherent capacity for complex protein folding and post-translational modifications (2).”
Novel cell line development strategy for monoclonal antibody manufacturing using translational enhancing technology
Masuda, K., Watanabe, K., Ueno, T., Nakazawa, Y., Tanabe, Y., Ushiki‐Kaku, Y., Ogawa‐Goto, K., Ehara, Y., Saeki, H., Okumura, T., et al. (2021) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2021.11.010 · Cited by 11
Precision analysis for the determination of steric mass action parameters using eight tobacco host cell proteins.
Bernau, C. R., Jäpel, R., Hübbers, J. W., Nölting, S., Opdensteinen, P., & Buyel, J. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462379 · Cited by 11
Cell Pool Selection of CHO Host and Recombinant Cell Pools by Inhibition of the Proteasome Results in Enhanced Product Yields and Cell Specific Productivity.
Knight, T. J., Turner, S. J., Jaques, C., & Smales, C. (2021) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2021.06.019 · Cited by 11
“correctly fold, assemble and secrete multi-domain/polypeptide chain containing molecules with high yield and quality (Feary, 2017; Kunert, 2016; Mead, 2015; Povey, 2014; Walsh, 2018).”
Background
Engineering of Chinese Hamster Ovary Cells With NDPK-A to Enhance DNA Nuclear Delivery Combined With EBNA1 Plasmid Maintenance Gives Improved Exogenous Transient Reporter, mAb and SARS-CoV-2 Spike Protein Expression
Budge, J. D., Young, R. J., & Smales, C. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.679448 · Cited by 11
“…| Volume 9 | Article 679448 recombinant products in the clinic has consistently increased in recent years largely due to an increase in the number of mAb approvals but also as a result of the emergence of novel format molecules such as Fc-fusion proteins and bispecific antibodies (Walsh, 2018).”
Background
Strategies and Applications of Antigen-Binding Fragment (Fab) Production in Escherichia coli
Chen, H., Chen, J.-S., Paerhati, P., Jakoš, T., Bai, S., Zhu, J., & Yuan, Y. (2021) · Pharmaceutical Fronts · doi:10.1055/s-0041-1735145 · Cited by 10
Modulation of high mannose levels in N ‐linked glycosylation through cell culture process conditions to increase antibody‐dependent cell‐mediated cytotoxicity activity for an antibody biosimilar
Rameez, S., Gowtham, Y. K., Nayar, G., & Mostafa, S. S. (2021) · Biotechnology Progress · doi:10.1002/btpr.3176 · Cited by 10
“, N-acetylglucosamine [GlcNAc], mannose [Man], fucose, galactose, and sialic acid) are assembled with complex combinations to form a repertoire of glycosylation patterns.(1)”
Background
High shear resistance of insect cells: the basis for substantial improvements in cell culture process design
Strobl, F., Duerkop, M., Palmberger, D., & Striedner, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-88813-4 · Cited by 11
“With a two-way valve (3), the cells could either be hoovered from the sample reservoir (1) into the syringe pump (2) or, when the valve was switched, cells were pumped from the syringe pump (2) through an orifice (4), and into the sample collector (5).”
BackgroundMethodInfluential
‘Omics driven discoveries of gene targets for apoptosis attenuation in CHO cells
Orellana, C. A., Martínez, V. S., MacDonald, M. A., Henry, M. N., Gillard, M., Gray, P. P., Nielsen, L. K., Mahler, S. M., & Marcellin, E. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27548 · Cited by 13
“The biopharmaceutical industry is fast growing, with global sales of over USD 188 billion in 2017 (Walsh, 2018).”
BackgroundInfluential
Toward Antibody Production in Genome-Minimized Bacillus subtilis Strains
Schilling, T., Biedendieck, R., Morán‐Torres, R., Saaranen, M. J., Ruddock, L. W., Daniel, R., & van Dijl, J. M. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00688 · Cited by 11
Anti-Inflammatory Effects of Helminth-Derived Products: Potential Applications and Challenges in Diabetes Mellitus Management
Zhu, Y., Chen, X., Zheng, H., Ma, Q., Chen, K., & Li, H. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s493374 · Cited by 9
SEMPER: Stoichiometric expression of mRNA polycistrons by eukaryotic ribosomes for compact, ratio-tunable multi-gene expression
Duan, M., Dev, I., Lu, A. Y., Ayrapetyan, G., You, M. Y., & Shapiro, M. G. (2024) · Cell Systems · doi:10.1016/j.cels.2024.06.001 · Cited by 15
Development of generic metabolic Raman calibration models using solution titration in aqueous phase and data augmentation for in‐line cell culture analysis
Zhang, Z., Lang, Z., Chen, G., Zhou, H., & Zhou, W. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28717 · Cited by 10
Computer-aided design space identification for screening of protein A affinity chromatography resins.
Sachio, S., Likozar, B., Kontoravdi, C., & Papathanasiou, M. M. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464890 · Cited by 10
When will we have a clone? An industry perspective on the typical CLD timeline
Clarke, H., Mayer-Bartschmid, A., Zheng, C., Masterjohn, E., Patel, F. N., Moffat, M. A., Wei, Q., Liu, R., Emmins, R., Fischer, S., et al. (2024) · Biotechnology progress (Print) · doi:10.1002/btpr.3449 · Cited by 10
In pursuit of a minimal CHO genome: Establishment of large-scale genome deletions
Jerabek, T., Weiß, L., Fahrion, H., Zeh, N., Raab, N., Lindner, B., Fischer, S., & Otte, K. (2023) · New Biotechnology · doi:10.1016/j.nbt.2023.12.007 · Cited by 10
Genome‐wide CRISPR/Cas9 knockout screening to mitigate cell growth inhibition induced by histone deacetylase inhibitors in recombinant CHO cells
Kim, D., Kim, S. H., Yoon, C., & Lee, G. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28611 · Cited by 10
“Increasing demand for therapeutic proteins necessitates the improvement of the productivity of Chinese hamster ovary (CHO) cells that are widely used for therapeutic protein production (Walsh, 2018; Wurm, 2004).”
Background
Boosting Productivity for Advanced Biomanufacturing by Re-Using Viable Cells
Reger, L. N., Saballus, M., Matuszczyk, J., Kampmann, M., Wijffels, R. H., Martens, D. E., & Niemann, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1106292 · Cited by 10
“…bed centrifuge, intermediate 9 harvest, monoclonal antibodies 1 Introduction Recombinantly expressed biotherapeutics, such as monoclonal antibodies (mAb), hormones, cytokines, and vaccines, have gained attention in the pharmaceutical industry during recent years (Walsh, 2018).”
Background
Effects and mechanisms of animal-free hydrolysates on recombination protein yields in CHO cells
Du, Q.-J., Zhang, X., Wang, T., & Wang, X. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12229-x · Cited by 14
“Walsh’s report indicated that 54 of the 67 monoclonal antibodies (mAb) approved from 2014 to 2018 in the market were made in CHO cells (Walsh 2018).”
Background
Current Strategies to Improve Yield of Recombinant Protein Production in Rice Suspension Cells
Chi, Y., & Huang, L.-F. (2022) · Processes · doi:10.3390/pr10061120 · Cited by 10
Strategies for developing a recombinant butyrylcholinesterase medical countermeasure for Organophosphorus poisoning
Allard, J. L., Shields, K. A., Munro, T. P., & Lua, L. H. L. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109996 · Cited by 14
A General Small-Angle X-ray Scattering-Based Screening Protocol for Studying Physical Stability of Protein Formulations
Zhang, F., Richter, G., Bourgeois, B. M. R., Spreitzer, E., Moser, A., Keilbach, A., Kotnik, P., & Madl, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010069 · Cited by 10
“Biopharmaceutical products represent an increasing percentage in drug development and new drug applications for market approval [3], but their commercial and academic usage is currently limited by their physical stability.”
Background
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
Alsamil, A. M., Giezen, T., Egberts, T., Leufkens, H., & Gardarsdottir, H. (2021) · Pharmaceuticals · doi:10.3390/ph14030189 · Cited by 10
“Biological drugs have become important treatment options for numerous diseases, including cancer and inflammatory diseases [1].”
Background
Regulation of pyruvate dehydrogenase complex related to lactate switch in CHO cells
Möller, J., Bhat, K., Guhl, L., Pörtner, R., Jandt, U., & Zeng, A. (2020) · Engineering in Life Sciences · doi:10.1002/elsc.202000037 · Cited by 13
IGF1 inclusion bodies: A QbD based process approach for efficient USP as well as early DSP unit operations
Metzger, K. F. J., Padutsch, W., Pekarsky, A., Kopp, J., Voloshin, A. M., Kühnel, H., & Maurer, M. (2020) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2020.02.014 · Cited by 10
Subphysiological temperature induces pervasive alternative splicing in Chinese hamster ovary cells
Tzani, I., Monger, C., Motheramgari, K., Gallagher, C., Hagan, R., Kelly, P. S., Costello, A., Meiller, J., Floris, P., Zhang, L., et al. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27365 · Cited by 11
Development of an improved lentiviral based vector system for the stable expression of monoclonal antibody in CHO cells
Mohammadian, O., Rajabibazl, M., Pourmaleki, E., Bayat, H., Ahani, R., & Rahimpour, A. (2019) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2019.1621893 · Cited by 10
“As the result, mAbs have become the best-selling and most abundant type of recombinant products in the market.([2,3]) The production of mAbs is a multi-billion dollar trade; as by 2016, worldwide sales of these products were around $100 billion and it is estimated that this value will increase further in the coming ye…”
Background
Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems
Top, O., Geisen, U., Decker, E., & Reski, R. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.00261 · Cited by 10
“The global market value of recombinant coagulation factors was approximately $8.5 billion in 2017 (Walsh, 2018).”
BackgroundInfluential
Molecular chaperones: A revolutionary approach for increased solubility of recombinant mAbs from bacterial and yeast systems
Kulkarni, N. A., Das, P. K., Arjun, P., & Veeranki, V. D. (2025) · Protein Expression and Purification · doi:10.1016/j.pep.2025.106764 · Cited by 10
Profiling the diversity of the village chicken faecal microbiota using 16S rRNA gene and metagenomic sequencing data to reveal patterns of gut microbiome signatures
Nene, M., Kunene, N., Pierneef, R., & Hadebe, K. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1487595 · Cited by 9
Genome‐Scale Modeling of CHO Cells Unravel the Critical Role of Asparagine in Cell Culture Feed Media
Pang, K., Hong, Y.-F., Shozui, F., Furomitsu, S., Myint, M., Ho, Y., Silberberg, Y. R., Walsh, I., & Lakshmanan, M. (2024) · Biotechnology Journal · doi:10.1002/biot.202400072 · Cited by 9
Strategies to improve CHO cell culture performance: Targeted deletion of amino acid catabolism and apoptosis genes paired with growth inhibitor supplementation
Lam, C., Sargon, A. B., Diaz, C., Lai, Z., Sangaraju, D., Yuk, I. H. Y., Barnard, G. C., & Misaghi, S. (2024) · Biotechnology Progress · doi:10.1002/btpr.3471 · Cited by 7
High‐efficiency and multilocus targeted integration in CHO cells using CRISPR‐mediated donor nicking and DNA repair inhibitors
Hamaker, N. K., & Lee, K. H. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28393 · Cited by 9
“Furthermore, these methods must provide robust improvements to achieve multilocus targeted integration of RMCE landing pads to support commercial manufacturing of complex therapeutic modalities such as bispecific and trispecific mAbs (Spiess et al., 2015; Walsh, 2018).”
BackgroundMethod
Engineering protein glycosylation in CHO cells to be highly similar to murine host cells
Gupta, S., Shah, B., Fung, C., Chan, P. K., Wakefield, D. L., Kuhns, S., Goudar, C., & Piret, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1113994 · Cited by 9
“Recombinant therapeutic proteins, also known as biologics, have been successfully used to treat a wide range of diseases, including cancers, inflammatory disorders, and cardiovascular diseases (Walsh, 2018).”
Background
High‐throughput capillary electrophoresis analysis of biopharmaceuticals utilizing sequential injections
Kumar, R., Sarin, D., & Rathore, A. S. (2023) · ELECTROPHORESIS · doi:10.1002/elps.202200208 · Cited by 10
“Monoclonal antibodies (mAbs) presently form the bulk of biopharmaceutical pipelines [1].”
Background
The role of process systems engineering in applying quality by design (QbD) in mesenchymal stem cell production
Udugama, I. A., Badr, S., Hirono, K., Scholz, B. X., Hayashi, Y., Kino‐oka, M., & Sugiyama, H. (2023) · Computers & Chemical Engineering · doi:10.1016/j.compchemeng.2023.108144 · Cited by 9
Insights into the quality of recombinant proteins produced by two different Bombyx mori expression systems
Kajiura, H., Tatematsu, K., Nomura, T., Miyazawa, M., Usami, A., Tamura, T., Sezutsu, H., & Fujiyama, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-22565-7 · Cited by 9
The production of the first functional antibody mimetic in higher plants: the chloroplast makes the DARPin G3 for HER2 imaging in oncology
Ehsasatvatan, M., Kohnehrouz, B. B., Gholizadeh, A., Ofoghi, H., & Shanehbandi, D. (2022) · Biological Research · doi:10.1186/s40659-022-00400-7 · Cited by 11
“Moreover, in the plant-based expression systems, folding and modification of proteins are more similar to human processes [77, 78].”
Background
A cleavable self-aggregating tag scheme for the expression and purification of disulfide bonded proteins and peptides
Lin, Z., Jing, Y., Huang, Y., Yang, S., Chen, S., Ou, Y.-Y., Pistolozzi, M., & Yang, X. (2022) · Chemical Engineering Science · doi:10.1016/j.ces.2022.118052 · Cited by 11
Polynorbornene-based bioconjugates by aqueous grafting-from ring-opening metathesis polymerization reduce protein immunogenicity
Church, D. C., Davis, E., Caparco, A. A., Takiguchi, L. P., Chung, Y. H., Steinmetz, N. F., & Pokorski, J. K. (2022) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2022.101067 · Cited by 11
In vitro/in vivo degradation analysis of trastuzumab by combining specific capture on HER2 mimotope peptide modified material and LC-QTOF-MS.
Lu, L., Liu, X., Zuo, C., Zhou, J.-W., Zhu, C., Zhang, Z., Fillet, M., Crommen, J., Jiang, Z.-J., & Wang, Q.-Q. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.340199 · Cited by 9
Engineering and validation of a dual luciferase reporter system for quantitative and systematic assessment of regulatory sequences in Chinese hamster ovary cells
Toktay, Y., Dayanc, B., & Şentürk, Ş. (2022) · Scientific Reports · doi:10.1038/s41598-022-09887-2 · Cited by 14
“To establish the utility of the reporter system, we modeled an experimental scheme based on systematic and quantitative comparison of a compendium of existing constitutive promoters in two contexts: (1) transient transfection of different CHO cell variants as well as HEK-293T cells, and (2) stable cultures of CHODG44…”
Method
Growth and eGFP Production of CHO-K1 Suspension Cells Cultivated From Single Cell to Laboratory Scale
Schmitz, J., Hertel, O., Yermakov, B., Noll, T., & Grünberger, A. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.716343 · Cited by 10
“Keywords: microfluidics, single-cell cultivation, single-cell analysis, miniaturization, scale comparison, cell culture, GFP production INTRODUCTION The number of biotechnologically manufactured products like biopharmaceuticals has increased rapidly over the last decades (Walsh, 2018).”
Background
A novel strategy for efficient expression of an antibody fragment in Escherichia coli : ranibizumab as a case study
Priyanka, P., & Rathore, A. (2021) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.6883 · Cited by 9
Leprosy detection rate in patients under immunosuppression for the treatment of dermatological, rheumatological, and gastroenterological diseases: a systematic review of the literature and meta-analysis
Barroso, D., Brandão, J. G., Andrade, E. S. N., Correia, A. C. B., Aquino, D., Chen, A. C., Vernal, S., de Araújo, W. D., da Mota, L. M. H., Sampaio, R. N., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06041-7 · Cited by 9
“They represent the most important pharmaceutical products sold in the US, as they are the treatments most frequently prescribed for inflammatory and autoimmune conditions [2].”
Background
Enhancing the yield and activity of defucosylated antibody produced by CHO-K1 cells using Cas13d-mediated multiplex gene targeting
Lin, M., Shen, C., Lin, Y.-J., Chou, M., Pham, N. N., Chang, Y., Chang, C.-W., Hwu, J. R., Nguyen, M. T. T., & Hu, Y. (2021) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2021.03.040 · Cited by 9
Probabilistic model by Bayesian network for the prediction of antibody glycosylation in perfusion and fed‐batch cell cultures
Zhang, L., Wang, M., Castan, A., Hjalmarsson, H., & Chotteau, V. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27769 · Cited by 11
“6% of the total biopharmaceutical global sales in 2017 (Walsh, 2018).”
BackgroundInfluential
LC-MS/MS-based quantitative proteomic and phosphoproteomic analysis of CHO-K1 cells adapted to growth in glutamine-free media
Kaushik, P., Curell, R. V., Henry, M. A., Barron, N., & Meleady, P. (2020) · Biotechnology Letters · doi:10.1007/s10529-020-02953-7 · Cited by 30
“Up to 85% of new monoclonal antibody (Mab) products approved between 2014 and 2018 were produced in Chinese hamster ovary (CHO) cells (Walsh 2018).”
Background
New insights on the interaction mechanism of rhTNFα with its antagonists Adalimumab and Etanercept
Contreras, M. A., Macaya, L., Neira, P., Camacho, F., González, A., Acosta, J., Montesino, R., Toledo, J., & Sánchez, O. (2020) · bioRxiv · doi:10.1101/2020.06.21.163824 · Cited by 9
In situ scanning capacitance sensor with spectral analysis reveals morphological states in cultures for production of biopharmaceuticals
Randek, J., & Mandenius, C. (2020) · doi:10.1016/j.snb.2020.128052 · Cited by 9
Highly sensitive HPLC analysis and biophysical characterization of N‐glycans of IgG‐Fc domain in comparison between CHO and 293 cells using FcγRIIIa ligand
Kosuge, H., Nagatoishi, S., Kiyoshi, M., Ishii‐Watabe, A., Tanaka, T., Terao, Y., Oe, S., Ide, T., & Tsumoto, K. (2020) · Biotechnology Progress · doi:10.1002/btpr.3016 · Cited by 8
“Antibodies have high specificity and efficacy.(1-3) More than 80 antibody drugs are currently approved by FDA,(4) most to treat cancer or autoimmune diseases.”
Background
Similar biologics in India
Jois, R., Mukherjee, S., Rajeswari, S., Rath, P., Goyal, V., & Gupta, D. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_43_18 · Cited by 16
Quantitative comparison of the N-glycosylation of therapeutic glycoproteins using the Glycosimilarity Index. A tutorial
Szekrényes, Á., Szigeti, M., Dvořáková, V., Járvás, G., & Guttman, A. (2020) · Trends in Analytical Chemistry (TrAC) · doi:10.1016/j.trac.2019.115728 · Cited by 9
Iterative learning robust optimization - with application to medium optimization of CHO cell cultivation in continuous monoclonal antibody production
Wang, Y., Pasquini, M., Chotteau, V., Hjalmarsson, H., & Jacobsen, E. W. (2024) · Journal of Process Control · doi:10.1016/j.jprocont.2024.103196 · Cited by 6
CellShip: An Ambient Temperature Transport and Short-Term Storage Medium for Mammalian Cell Cultures
Buick, E., Mead, A., Al-Hubaysh, A., Assi, P. B., Das, P., Dayus, J., Turner, M. C., Kowalski, L., Murray, J., Renshaw, D., et al. (2023) · Biopreservation and Biobanking · doi:10.1089/bio.2023.0100 · Cited by 8
“20 Despite its widespread use, methods for transporting cells remain largely unchanged, with cryopreservation being the most popular.”
Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies
Barnard, G. C., Zhou, M., Shen, A., Yuk, I. H., & Laird, M. W. (2023) · Biotechnology progress (Print) · doi:10.1002/btpr.3399 · Cited by 8
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Lee, J., Lee, N., Seo, Y. J., & Kim, I.-K. (2023) · BioDrugs · doi:10.1007/s40259-023-00581-x · Cited by 8
Life at the periphery: what makes CHO cells survival talents
Jerabek, T., Klingler, F., Raab, N., Zeh, N., Pfannstiel, J., & Otte, K. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-12123-6 · Cited by 10
“CHO cells continue to be the most frequently used mammalian expression system in the biopharmaceutical industry (Walsh 2018).”
Background
Generation of a host cell line containing a MAR ‐rich landing pad for site‐specific integration and expression of transgenes
Oliviero, C., Hinz, S. C., Bogen, J. P., Kornmann, H., Hock, B. M., Kolmar, H., & Hagens, G. (2022) · Biotechnology Progress · doi:10.1002/btpr.3254 · Cited by 7
“the current workhorse for recombinant protein expression using mammalian cells.(2,3) In 2017, the majority of the antibodies with the highest market share was produced in CHO cells.”
Background
New Perspectives for Developing Therapeutic Bioconjugates of Metabolite-Depleting Enzymes: Lessons Learned Combating Glutamate Excitotoxicity.
Zaghmi, A., Pérez-Mato, M., Dopico-López, A., Candamo-Lourido, M., Campos, F., & Gauthier, M. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00117 · Cited by 8
Predicting the Hydrodynamic Properties of a Bioreactor: Conditional Density Estimation as a Surrogate Model for CFD Simulations
Kaya, U., Gopireddy, S., Urbanetz, N., Nopens, I., & Verwaeren, J. (2022) · Chemical engineering research & design · doi:10.1016/j.cherd.2022.03.042 · Cited by 8
Energy metabolism in Chinese hamster ovary (CHO) cells: Productivity and beyond
Park, J. U., Han, H., & Baik, J. Y. (2022) · Korean Journal of Chemical Engineering · doi:10.1007/s11814-022-1062-y · Cited by 8
Genetically engineered birds; pre-CRISPR and CRISPR era
Dehdilani, N., Taemeh, S. Y., Goshayeshi, L., & Dehghani, H. (2021) · Biology of Reproduction · doi:10.1093/biolre/ioab196 · Cited by 21
“The last two decades have seen a growing trend towards the production and marketing of more than 150 billion US dollars worth of biopharmaceuticals [3].”
Background
Electrostatics Drive Oligomerization and Aggregation of Human Interferon Alpha-2a
Pohl, C., Polimeni, M., Indrakumar, S., Streicher, W., Peters, G. H., Nørgaard, A., Lund, M., & Harris, P. (2021) · Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c07090 · Cited by 8
“Currently two approaches are used to reduce aggregation: (1) finding a suitable formulation which is labor-intensive and requires large protein quantities or (2) engineering the protein by specific, stabilizing mutations, which requires specific knowledge about the protein aggregation pathway.”
Differential expression of miRNAs and functional role of mir-200a in high and low productivity CHO cells expressing an Fc fusion protein
Bryan, L., Henry, M., Barron, N., Gallagher, C., Kelly, R. M., Frye, C., Osborne, M., Clynes, M., & Meleady, P. (2021) · Biotechnology Letters · doi:10.1007/s10529-021-03153-7 · Cited by 8
“The Chinese hamster ovary (CHO) cell is widely accepted as the cell line of choice for the production of large scale commercial therapeutic proteins (Walsh 2018).”
Background
Effect of Poly(trehalose methacrylate) Molecular Weight and Concentration on the Stability and Viscosity of Insulin
Gelb, M. B., & Maynard, H. D. (2021) · Macromolecular Materials and Engineering · doi:10.1002/mame.202100197 · Cited by 8
Application of lectin immobilized on polyHIPE monoliths for bioprocess monitoring of glycosylated proteins
Stantič, M., Gunčar, G., Kuzman, D., Mravljak, R., Cvijić, T., & Podgornik, A. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122731 · Cited by 8
Wolffia arrhiza as a promising producer of recombinant hirudin
Khvatkov, P., Firsov, A., Shvedova, A., Kozlov, O., Chernobrovkina, M., Pushin, A., Shaloiko, L., & Dolgov, S. (2021) · 3 Biotech · doi:10.1007/s13205-021-02762-3 · Cited by 8
“Currently, the biopharming industry has a wide range of expression platforms (cells of bacteria, yeast, mammals and insects) for the production of therapeutic proteins (Walsh 2018; Rader and Langer 2015; Sysuev and Pokrovskaya 2015).”
Background
Investigating the influence of physiologically relevant hydrostatic pressure on CHO cell batch culture
Shang, M., Kwon, T., Hamel, J. P., Lim, C. T., Khoo, B. L., & Han, J. (2021) · Scientific Reports · doi:10.1038/s41598-020-80576-8 · Cited by 9
Error propagation in constraint‐based modeling of Chinese hamster ovary cells
Széliová, D., Iurashev, D., Ruckerbauer, D. E., Koellensperger, G., Borth, N., Melcher, M., & Zanghellini, J. (2020) · Biotechnology Journal · doi:10.1002/biot.202000320 · Cited by 6
“Chinese hamster ovary (CHO) cells are the primary host for the production of biopharmaceuticals, particularly monoclonal antibodies and other complex therapeutic proteins 1 .”
Background
S‐adenosylmethionine and methylthioadenosine boost cellular productivities of antibody forming Chinese hamster ovary cells
Verhagen, N., Teleki, A., Heinrich, C., Schilling, M., Unsoeld, A., & Takors, R. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27484 · Cited by 9
“Therapeutic proteins such as monoclonal antibodies (mAB) dominate the global market for biopharmaceuticals and are mostly produced in Chinese hamster ovary (CHO) cells (Walsh, 2018).”
Background
Strategies to improve the expression and solubility of recombinant proteins in E. coli
Nag, N., Khan, H., & Tripathi, T. (2022) · Advances in Protein Molecular and Structural Biology Methods · doi:10.1016/b978-0-323-90264-9.00001-5 · Cited by 8
Global phosphoproteomic study of high/low specific productivity industrially relevant mAb producing recombinant CHO cell lines
Bryan, L., Henry, M., Kelly, R. M., Lloyd, M. E., Frye, C., Osborne, M., Clynes, M., & Meleady, P. (2021) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2021.02.002 · Cited by 8
Process analytics 4.0: A paradigm shift in rapid analytics for biologics development
Wasalathanthri, D. P., Shah, R., Ding, J., Leone, A., & Li, Z. J. (2021) · Biotechnology Progress · doi:10.1002/btpr.3177 · Cited by 17
“Biotherapeutic modalities evolve rapidly to deliver unmet patient needs, which require the development and amendment of typical analytical assays for CQAs and CPPs.(80) Unlike manual assays, it would be challenging to simply amend or re-develop automated or PAT type real time analytical assays for specialized biologic…”
Method
NTxPred2: A large language model for predicting neurotoxic peptides and neurotoxins
Rathore, A., Jain, S., Choudhury, S., & Raghava, G. (2025) · bioRxiv · doi:10.1101/2025.03.01.640936 · Cited by 7
“In addition to sequencing, GM organisms, GM crops, and technology have played a key role in the large-scale production of therapeutic proteins like monoclonal antibodies and hormones (Plotkin, 2010; Walsh, 2018).”
Near UV and Visible Light-Induced Degradation of Bovine Serum Albumin and a Monoclonal Antibody Mediated by Citrate Buffer and Fe(III): Reduction vs Oxidation Pathways.
Wu, Y., Gardner, R. A., & Schöneich, C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00445 · Cited by 7
Ectoine enhances recombinant antibody production in Chinese hamster ovary cells by promoting cell cycle arrest
Jarusintanakorn, S., Mastrobattista, E., & Yamabhai, M. (2024) · New Biotechnology · doi:10.1016/j.nbt.2024.06.006 · Cited by 8
Prediction of antibody production performance change in Chinese hamster ovary cells using morphological profiling
Hisada, T., Imai, Y., Takemoto, Y., Kanie, K., & Kato, R. (2024) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2024.01.011 · Cited by 7
Automated Raman feed-back control of multiple supplemental feeds to enable an intensified high inoculation density fed-batch platform process
Webster, T. A., Hadley, B. C., Dickson, M. R., Hodgkins, J., Olin, M., Wolnick, N., Armstrong, J., Mason, C., & Downey, B. J. (2023) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-023-02912-2 · Cited by 14
“Monoclonal antibodies (mAbs) in particular are expected to continue to be in high demand as different modalities and targets are identified [1].”
Background
Optimisation of recombinant TNFα production in Escherichia coli using GFP fusions and flow cytometry
Zulkifly, N. A. H., Castiñeiras, T. S., & Overton, T. W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1171823 · Cited by 7
“E. coli is an advantageous host for relatively simple proteins that do not require post-translational modi ﬁ cations such as glycosylation (Overton, 2014; Sanchez-Garcia et al., 2016); example products include insulin, granulocyte-colony stimulating factor and antibody fragments (Walsh, 2018).”
Monitoring mAb proteoforms in mouse plasma using an automated immunocapture combined with top‐down and middle‐down mass spectrometry
Dhenin, J., Lafont, V., Dupré, M., Krick, A., Mauriac, C., & Chamot‐Rooke, J. (2023) · PROTEOMICS · doi:10.1002/pmic.202300069 · Cited by 7
Comparability strategy and demonstration for post-approval production cell line change of a bevacizumab biosimilar IBI305
Wu, Z., Xu, G.-L., He, W., Yu, C., Huang, W., Zheng, S.-R., Kang, D., Xie, M. H., Cao, X.-J., Wang, L., et al. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad017 · Cited by 7
In-depth size and charge variants characterization of monoclonal antibody with native mass spectrometry
Dai, J., & Ji, C. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341360 · Cited by 7
Strategies for controlling afucosylation in monoclonal antibodies during upstream manufacturing
Rish, A. J., Siddiquee, K., Huang, Z., Xu, J., Anderson, C. A., Borys, M., & Khetan, A. (2023) · Biotechnology Journal · doi:10.1002/biot.202200604 · Cited by 8
“[3] Due to this, mammalian cells are the preferred host vector for themanufacturing ofmAbs as the glycosylation patterns observed from these cells are similar to those in humans.[1] In contrast, mAbs produced in other types of cells such as”
Background
Immortal orexin cell transplants restore motor-arousal synchrony during cataplexy
Pintwala, S. K., Fraigne, J. J., Belsham, D. D., & Peever, J. H. (2023) · Current Biology · doi:10.1016/j.cub.2023.03.077 · Cited by 9
Application of a Novel Aptamer Beacon for Rapid Detection of IgG1 Antibody Drugs
Yang, K., Zheng, W.-W., Huang, X.-S., Chen, K., & Duan, C. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04471-4 · Cited by 7
“Monoclonal antibodies are increasingly advantageous in the biopharmaceutical field, and many monoclonal antibodies are expressed in mammalian systems [25].”
Background
High-Throughput Counting and Sizing of Therapeutic Protein Aggregates in the Nanometer Size Range by Nano-Flow Cytometry.
Gao, K., Lian, H.-X., Xue, C.-F., Zhou, J., & Yan, X.-M. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c04382 · Cited by 7
A Novel Tandem-Tag Purification Strategy for Challenging Disordered Proteins
Mészáros, A., Muwonge, K., Janvier, S., Ahmed, J., & Tompa, P. (2022) · Biomolecules · doi:10.3390/biom12111566 · Cited by 10
“In the last few years, close to 100 new biopharmaceuticals, the majority being recombinant proteins, have entered the market [2].”
Background
Secretion of functional α1-antitrypsin is cell type dependent: Implications for intramuscular delivery for gene therapy
Ke, H., Guay, K. P., Flotte, T. R., Gierasch, L. M., Gershenson, A., & Hebert, D. N. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206103119 · Cited by 9
“of biologics that traverse the secretory pathway (49, 50).”
Background
The Impact of Glycoengineering on the Endoplasmic Reticulum Quality Control System in Yeasts
Piirainen, M. A., & Frey, A. D. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.910709 · Cited by 7
“The yeast-based biopharmaceuticals currently in market include various insulin products and vaccines, but also other peptide hormones, a blood clotting factor subunit and a recombinant urate oxidase (Walsh, 2018).”
Background
Compartment‐specific 13C metabolic flux analysis reveals boosted NADPH availability coinciding with increased cell‐specific productivity for IgG1 producing CHO cells after MTA treatment
Wijaya, A. W., Verhagen, N., Teleki, A., & Takors, R. (2021) · Engineering in Life Sciences · doi:10.1002/elsc.202100057 · Cited by 8
“Engineering in Life Sciences published by Wiley-VCH GmbH share [1].”
Method
Middle-up characterization of monoclonal antibodies by online reduction liquid chromatography-mass spectrometry.
Verscheure, L., Oosterlynck, M., Cerdobbel, A., Sandra, P., Lynen, F., & Sandra, K. (2020) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.461808 · Cited by 7
A microfluidic chip for screening high-producing hybridomas at single cell level
Zhang, W., Li, R., Jia, F., Hu, Z., Li, Q., & Wei, Z. (2020) · Lab on a Chip · doi:10.1039/d0lc00847h · Cited by 17
Hydrofoam and oxygen headspace bioreactors improve cell‐free therapeutic protein production yields through enhanced oxygen transport
Nelson, J. A., Barnett, R. J., Hunt, J. P., Foutz, I., Welton, M., & Bundy, B. C. (2020) · Biotechnology Progress · doi:10.1002/btpr.3079 · Cited by 10
“In 2018, recombinant proteins accounted for 87% of all newly approved biopharmaceuticals and topped small molecules for the first time when considering the top 100 pharmaceuticals by worldwide sales.(3) Due to its fast growth, simple culturing procedure and cost-effectiveness, Escherichia.”
Background
CRISPR-Cas9 Genome Editing Tool for the Production of Industrial Biopharmaceuticals
Khan, A. H., Tye, G. J., & Noordin, R. (2020) · Molecular Biotechnology · doi:10.1007/s12033-020-00265-9 · Cited by 11

Authors: Walsh, G.
Affiliations: University of Limerick (IE)
Corresponding author: Walsh, Gary
ORCID: Walsh, Gary
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2018-12
Volume: 36
Issue: 12
Pages: 1136-1145
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.4305
OpenAlex: W2917928050
Cited by: 978
References: 15
Citations by year: 2026: 68 · 2025: 68 · 2024: 88 · 2023: 141 · 2022: 173 · 2021: 197 · 2020: 173 · 2019: 65
FWCI: 165.34
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: biopharmaceutical market, monoclonal antibodies, cell therapy, gene therapy, biosimilars, biologics, market growth
MeSH terms: Animals, Antibodies, Monoclonal, Biological Products, Biotechnology, Drug Industry, European Union, Humans, Nucleic Acids, Recombinant Proteins, United States, United States Food and Drug Administration, Drug Approval, Benchmarking, Biosimilar Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Biopharmaceutical benchmarks 2018

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks